• Je něco špatně v tomto záznamu ?

Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access

K. Pavelka, N. Akkoç, M. Al-Maini, CAF. Zerbini, DE. Karateev, EL. Nasonov, MU. Rahman, R. Pedersen, A. Dinh, Q. Shen, R. Vasilescu, S. Kotak, E. Mahgoub, B. Vlahos,

. 2017 ; 37 (9) : 1469-1479. [pub] 20170609

Jazyk angličtina Země Německo

Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc18033872
E-zdroje Online Plný text

NLK ProQuest Central od 1997-03-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2000-12-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-03-01 do Před 1 rokem

Odkazy

PubMed 28597306
DOI 10.1007/s00296-017-3749-7
Knihovny.cz E-zdroje

In this transglobal, randomized, double-blind, placebo-controlled, treat-to-target study, the maintenance of efficacy was compared between biologic-and biologic-free-disease-modifying antirheumatic drug (DMARD) combination regimens after low disease activity (LDA) was achieved with biologic DMARD induction therapy. Patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy received open-label etanercept 50 mg subcutaneously once weekly plus methotrexate with or without other conventional synthetic (cs) DMARDs for 24 weeks. Patients achieving LDA [disease activity score in 28 joints based on erythrocyte sedimentation rate (DAS28-ESR) <3.2] at week 24 were randomized to receive etanercept-methotrexate combination therapy or placebo-methotrexate combination therapy, with or without other csDMARDs, for 28 weeks. In the open-label period, 72% of patients achieved DAS28-ESR LDA at week 24. Patients enrolled in the double-blind period had long-standing rheumatoid arthritis and high disease activity at baseline (mean duration, 8.1 years; DAS28-ESR, 6.4). In the etanercept and placebo combination groups, 44% versus 17% achieved DAS28-ESR LDA and 34 versus 13% achieved DAS28-ESR remission at week 52 (p < 0.001). Adverse events were reported in 37 and 43%, serious adverse events in 0 and 4%, and serious infections in 0 and 2% in these groups, respectively, in the double-blind period. After induction of response with etanercept combination therapy following a treat-to-target approach in patients with long-standing rheumatoid arthritis and high disease activity at baseline, the etanercept combination regimen was significantly more effective in maintaining LDA and remission than a biologic-free regimen. ClinicalTrials.gov identifier. NCT01578850.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033872
003      
CZ-PrNML
005      
20181012121127.0
007      
ta
008      
181008s2017 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00296-017-3749-7 $2 doi
035    __
$a (PubMed)28597306
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Pavelka, Karel $u Institute and Clinic of Rheumatology 1st Medical Faculty, Charles University, Prague, Czech Republic. Pavelka@revma.cz.
245    10
$a Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access / $c K. Pavelka, N. Akkoç, M. Al-Maini, CAF. Zerbini, DE. Karateev, EL. Nasonov, MU. Rahman, R. Pedersen, A. Dinh, Q. Shen, R. Vasilescu, S. Kotak, E. Mahgoub, B. Vlahos,
520    9_
$a In this transglobal, randomized, double-blind, placebo-controlled, treat-to-target study, the maintenance of efficacy was compared between biologic-and biologic-free-disease-modifying antirheumatic drug (DMARD) combination regimens after low disease activity (LDA) was achieved with biologic DMARD induction therapy. Patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy received open-label etanercept 50 mg subcutaneously once weekly plus methotrexate with or without other conventional synthetic (cs) DMARDs for 24 weeks. Patients achieving LDA [disease activity score in 28 joints based on erythrocyte sedimentation rate (DAS28-ESR) <3.2] at week 24 were randomized to receive etanercept-methotrexate combination therapy or placebo-methotrexate combination therapy, with or without other csDMARDs, for 28 weeks. In the open-label period, 72% of patients achieved DAS28-ESR LDA at week 24. Patients enrolled in the double-blind period had long-standing rheumatoid arthritis and high disease activity at baseline (mean duration, 8.1 years; DAS28-ESR, 6.4). In the etanercept and placebo combination groups, 44% versus 17% achieved DAS28-ESR LDA and 34 versus 13% achieved DAS28-ESR remission at week 52 (p < 0.001). Adverse events were reported in 37 and 43%, serious adverse events in 0 and 4%, and serious infections in 0 and 2% in these groups, respectively, in the double-blind period. After induction of response with etanercept combination therapy following a treat-to-target approach in patients with long-standing rheumatoid arthritis and high disease activity at baseline, the etanercept combination regimen was significantly more effective in maintaining LDA and remission than a biologic-free regimen. ClinicalTrials.gov identifier. NCT01578850.
650    _2
$a dospělí $7 D000328
650    _2
$a antirevmatika $x aplikace a dávkování $x škodlivé účinky $7 D018501
650    _2
$a revmatoidní artritida $x diagnóza $x farmakoterapie $x patofyziologie $7 D001172
650    _2
$a biologické přípravky $x aplikace a dávkování $x škodlivé účinky $7 D001688
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a etanercept $x aplikace a dávkování $x škodlivé účinky $7 D000068800
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a methotrexát $x aplikace a dávkování $x škodlivé účinky $7 D008727
650    _2
$a lidé středního věku $7 D008875
650    _2
$a indukce remise $7 D012074
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Akkoç, Nurullah $u Division of Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey.
700    1_
$a Al-Maini, Mustafa $u Rheumatology, Allergy and Clinical Immunology Division, Mafraq Hospital, Abu Dhabi, United Arab Emirates.
700    1_
$a Zerbini, Cristiano A F $u Department of Rheumatology, Centro Paulista de Investigação Clinica, São Paulo, Brazil.
700    1_
$a Karateev, Dmitry E $u V. A. Nasonova Research Institute of Rheumatology, Moscow, Russia.
700    1_
$a Nasonov, Evgeny L $u V. A. Nasonova Research Institute of Rheumatology, Moscow, Russia.
700    1_
$a Rahman, Mahboob U $u Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA.
700    1_
$a Pedersen, Ronald $u Pfizer, Collegeville, PA, USA.
700    1_
$a Dinh, Andrew $u Pfizer, Collegeville, PA, USA.
700    1_
$a Shen, Qi $u Pfizer, Collegeville, PA, USA.
700    1_
$a Vasilescu, Radu $u Pfizer Global Innovative Pharma Business, Brussels, Belgium.
700    1_
$a Kotak, Sameer $u Pfizer, New York, NY, USA.
700    1_
$a Mahgoub, Ehab $u Pfizer, Collegeville, PA, USA.
700    1_
$a Vlahos, Bonnie $u Pfizer, Collegeville, PA, USA.
773    0_
$w MED00004228 $t Rheumatology international $x 1437-160X $g Roč. 37, č. 9 (2017), s. 1469-1479
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28597306 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181012121619 $b ABA008
999    __
$a ok $b bmc $g 1340330 $s 1030866
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 37 $c 9 $d 1469-1479 $e 20170609 $i 1437-160X $m Rheumatology international $n Rheumatol Int $x MED00004228
LZP    __
$a Pubmed-20181008

Najít záznam

Citační ukazatele

Možnosti archivace